Posts

Shadow AI in Healthcare 2026: Dos and Don'ts for Organizations

*Don'ts : * Avoid entering Protected Health Information (PHI) into unauthorized AI tools like ChatGPT without a Business Associate Agreement (BAA), as this violates HIPAA. 1 *Do : * Develop clear AI use policies defining approved tools, prohibiting consumer AI for patient data, and outlining approval processes with consequences for violations. 1 2 *Do : * Establish multidisciplinary AI governance councils including clinical, IT, cybersecurity, ethics, and legal experts to evaluate tools and enable secure innovation. 2 3 *Do : * Implement Data Loss Prevention (DLP) controls to block patient data from public AI platforms and run education campaigns on appropriate AI use. 3 *Don't : * React by completely blocking AI access, as this frustrates clinicians and leads to workarounds; instead, provide approved alternatives like ambient AI scribes. 1 3 *Do : * Communicate AI policies clearly, measure ROI, and budget for enterprise AI solutions to reduce documentatio...

Jeito Capital Raises Record $1.2 Billion for Jeito II Fund, Largest Ever for Independent European Biopharma Fund

Pfizer Closes South San Francisco Office, Transitions Employees to Remote Roles

Insmed Shelves Brinsupri for Hidradenitis Suppurativa After Phase 2b Failure

Sanofi's Bispecific Lunskeimig Succeeds in Asthma and Sinusitis Phase 2 Trials, Falls Short in Eczema

Gilead Continues Dealmaking Streak with $3.15B Tubulis Buy for ADCs

White House Adds AbbVie's Humira to TrumpRx at 86% Discount Alongside Biosimilars and Other Drugs

Sidewinder Therapeutics Announces $137 Million Series B Financing for Bispecific ADC Development

Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

Sanofi's Bispecific Scores Double Respiratory Phase 2 Wins but Flunks Eczema Study

AI in Medical Communications: Where Human Expertise Still Matters

ImmunityBio Responds to FDA Warning on Anktiva Promotional Claims with New Protocols

Gilead Acquires Tubulis for $3.15B Upfront to Strengthen Oncology ADC Pipeline